Drug profile · INN
cisatracurium besylate
CISATRACURIUM BESYLATE
cisatracurium besylate (CISATRACURIUM BESYLATE) is a muscle-type nicotinic acetylcholine receptor antagonist. Route of administration: injection. Current US regulatory status: approved.
Drug details — cisatracurium besylate
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 1
- Data quality
- 0.84
Quick answer
cisatracurium besylate (CISATRACURIUM BESYLATE) is a muscle-type nicotinic acetylcholine receptor antagonist. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Muscle-type nicotinic acetylcholine receptor antagonist
Primary target: Muscle-type nicotinic acetylcholine receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is cisatracurium besylate?
cisatracurium besylate (CISATRACURIUM BESYLATE) is a muscle-type nicotinic acetylcholine receptor antagonist. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for cisatracurium besylate?
CISATRACURIUM BESYLATE is a marketed brand name for cisatracurium besylate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of cisatracurium besylate?
cisatracurium besylate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.